Honjo T, Watanabe A
Jpn J Antibiot. 1984 Oct;37(10):1788-92.
Approximately 20 mg/kg/day of sulbactam/cefoperazone (SBT/CPZ) was given by one shot intravenous injection to 16 pediatric inpatients with respiratory tract infections (13 cases), urinary tract infection (1 case), skin infection (1 case) or gastrointestinal tract infection (1 case). An excellent efficacy in 6 cases and a good efficacy in 10 cases were observed. Causative organisms were not identified in the respiratory tract infections, even though the efficacy was excellent or good. Side effects were not noticed in particular and SBT/CPZ was judged as safe enough agent. Concentrations of SBT/CPZ in the spinal fluid were determined in 3 patients. Their low concentrations suggested the poor transfer into the spinal fluid. Finally, SBT/CPZ is a very useful agent since it is effective also against resistant organisms which produce penicillinase-type beta-lactamases.
对16例患有呼吸道感染(13例)、尿路感染(1例)、皮肤感染(1例)或胃肠道感染(1例)的儿科住院患者,按每日20mg/kg的剂量静脉注射舒巴坦/头孢哌酮(SBT/CPZ)。观察到6例疗效极佳,10例疗效良好。呼吸道感染病例中未鉴定出病原体,尽管疗效极佳或良好。未特别注意到副作用,SBT/CPZ被判定为足够安全的药物。对3例患者测定了脑脊液中SBT/CPZ的浓度。其浓度较低表明向脑脊液中的转运较差。最后,SBT/CPZ是一种非常有用的药物,因为它对产生青霉素酶型β-内酰胺酶的耐药菌也有效。